Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients

The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2

(2014) G. Mignot et al.   JOURNAL OF IMMUNOLOGY

Trans-Presentation of IL-15 Dictates IFN-Producing Killer Dendritic Cells Effector Functions

(2014) E. Ullrich et al.   JOURNAL OF IMMUNOLOGY

Exploiting antitumor immunity to overcome relapse and improve remission duration

(2011) Lei L. Chen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

(2011) Nicolas F Delahaye et al.   NATURE MEDICINE

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib

(2010) Joan Maurel et al.   CANCER

Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice

(2009) Benoît Hosten et al.   ANTI-CANCER DRUGS

The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC

(2009) NJ Liptrott et al.   BRITISH JOURNAL OF PHARMACOLOGY

Natural Killer Cell IFN-  Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients

(2009) C. Menard et al.   CANCER RESEARCH

Phase II Trial of Docetaxal Plus Imatinib Mesylate in the Treatment of Patients With Metastatic Breast Cancer

(2009) Denise A. Yardley et al.   Clinical Breast Cancer

Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders

(2009) N. Singh et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis

(2008) Daniela Matei et al.   CANCER

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY